CN1285836A - 3′－差向异构的K－252a衍生物 - Google Patents

3′－差向异构的K－252a衍生物 Download PDF

Info

Publication number
CN1285836A
CN1285836A CN98812812A CN98812812A CN1285836A CN 1285836 A CN1285836 A CN 1285836A CN 98812812 A CN98812812 A CN 98812812A CN 98812812 A CN98812812 A CN 98812812A CN 1285836 A CN1285836 A CN 1285836A
Authority
CN
China
Prior art keywords
hydrogen
unsubstituted
substituted
lower alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98812812A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·L·赫德金斯
黛安娜·E·金里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of CN1285836A publication Critical patent/CN1285836A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN98812812A 1997-12-31 1998-12-30 3′－差向异构的K－252a衍生物 Pending CN1285836A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7026397P 1997-12-31 1997-12-31
US60/070,263 1997-12-31

Publications (1)

Publication Number Publication Date
CN1285836A true CN1285836A (zh) 2001-02-28

Family

ID=22094212

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98812812A Pending CN1285836A (zh) 1997-12-31 1998-12-30 3′－差向异构的K－252a衍生物

Country Status (15)

Country Link
US (2) US6093713A (enExample)
EP (1) EP1044203B1 (enExample)
JP (1) JP4405667B2 (enExample)
KR (1) KR20010033737A (enExample)
CN (1) CN1285836A (enExample)
AT (1) ATE234308T1 (enExample)
AU (1) AU1947499A (enExample)
BR (1) BR9814543A (enExample)
CA (1) CA2315953C (enExample)
DE (1) DE69812177T2 (enExample)
DK (1) DK1044203T3 (enExample)
ES (1) ES2194385T3 (enExample)
NO (1) NO20003397L (enExample)
PT (1) PT1044203E (enExample)
WO (1) WO1999033836A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE301661T1 (de) 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
DE10161940A1 (de) 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
US6723844B1 (en) * 2003-02-27 2004-04-20 Abbott Laboratories Preparation of K-252a
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
AU2007334381B2 (en) * 2006-12-14 2014-02-13 Tautatis, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
WO1994027982A1 (en) 1993-05-28 1994-12-08 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
CA2170888A1 (en) * 1994-07-04 1996-01-18 Masahiko Kinugawa Process for producing indolocarbazole derivative
AU6657596A (en) 1995-07-31 1997-02-26 Ciba-Geigy Ag Trindene compounds
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis

Also Published As

Publication number Publication date
ES2194385T3 (es) 2003-11-16
WO1999033836A9 (en) 2000-09-14
JP2001527079A (ja) 2001-12-25
DE69812177T2 (de) 2004-01-15
PT1044203E (pt) 2003-07-31
US6451786B1 (en) 2002-09-17
DK1044203T3 (da) 2003-07-14
AU1947499A (en) 1999-07-19
CA2315953A1 (en) 1999-07-08
KR20010033737A (ko) 2001-04-25
JP4405667B2 (ja) 2010-01-27
WO1999033836A1 (en) 1999-07-08
CA2315953C (en) 2010-11-09
DE69812177D1 (de) 2003-04-17
US6093713A (en) 2000-07-25
EP1044203B1 (en) 2003-03-12
EP1044203A1 (en) 2000-10-18
NO20003397L (no) 2000-08-31
NO20003397D0 (no) 2000-06-29
BR9814543A (pt) 2000-10-10
ATE234308T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
EP1595866B1 (en) Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome
US7655686B2 (en) Certain substituted spirocyclic lactams and use thereof as pharmaceuticals
CN1136219C (zh) 用于治疗阳痿的吡唑并嘧啶酮衍生物
CN1219841A (zh) 作为抗肿瘤剂的结合dna的吲哚衍生物,前药及其免疫轭合物
PL212956B1 (pl) Zastosowanie zwiazku o wzorze I lub II, zwiazek o wzorze II, oraz kompozycja farmaceutyczna zawierajaca zwiazek o wzorze II
JP2001519412A (ja) Ｃｃ−１０６５およびデュオカルマイシンのイソ−ｃｂｉおよびイソ−ｃｉ類似体
CN104736534A (zh) 用于治疗糖尿病及其相关紊乱症的2-苯基-5-杂环基-四氢-2h-吡喃-3-胺化合物
CN101679444A (zh) 具有正变构gabab受体调节剂作用的黄嘌呤化合物
BG65447B1 (bg) Инденопиролокарбазоли, съдържащи мостова връзка
CN1285836A (zh) 3′－差向异构的K－252a衍生物
WO2020156437A1 (zh) Akt抑制剂
EP2380892B1 (en) Imidazothiazole derivative having proline ring structure
CN1108658A (zh) 雪花胺衍生物及其制备方法和其作为药剂的用途
CN1087910A (zh) 5-取代的吡咯并[2，3-d]嘧啶的制备方法
CN1041930C (zh) [1,2,4]三唑并[4,3－a]喹喔啉衍生物,其制备及用途
CN1628116A (zh) αLβ2整合素介导的细胞粘附抑制剂
US20240083875A1 (en) Dihydroisoquinolinyl derivatives
RU2441876C2 (ru) Производное 3'-этинилцитидина
JP2022552834A (ja) ミエロペルオキシダーゼ阻害剤のプロドラッグ
EP0772615B1 (fr) DERIVES D'ACIDE IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-2-CARBOXYLIQUE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
EP1654241B1 (en) Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
CN1571793A (zh) 新的羟烷基吲哚并咔唑衍生物、制备方法和含有这些衍生物的药物组合物
FR2738821A1 (fr) Indeno[1,2-e]pyrazin-4-ones, leur preparation et les medicaments les contenant
MXPA00006500A (en) 3'-epimeric k-252a derivatives
AU2001285205B2 (en) Fused pyrrolocarbazoles against inflammation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication